SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is at a critical inflection point as the community focuses on the upcoming launch of BlueBird 7 and the company's commitment to ramping up satellite production cadence to meet aggressive 2026 deployment targets. Investors are actively debating the impact of recent insider selling against the backdrop of significant contracted revenue and institutional backing, with sentiment split between those viewing current volatility as a strategic entry point and others expressing skepticism over execution risks.

RaveDAO is a global community uniting music, technology, and purpose. Since their first sold-out event at Dubai 2024, they have expanded across Europe, the Middle East, North America, and Asia, hosting world-class experiences with over 100,000 total attendees and 3,000+ attendees for each event.  RaveDAO has worked with top-tier artists like Vintage Culture, Don Diablo, Chris Avantgarde, Lilly Palmer, MORTEN, Bassjackers, and GENESI and has support from Binance, OKX, Bitget, and Polygon. RaveDAO is redefining live entertainment in Web3 and has active partnerships with 1001Tracklists, AMF, and Warner Music.  Beyond the dance floor, RaveDAO channels energy and attention toward impact. In 2025 alone, proceeds from its events helped restore sight to 400+ cataract patients in Nepal and fund over 150 meditation programs across the U.S.

RaveDAO

RaveDAO is experiencing extreme volatility and intense community debate after a massive surge and subsequent sharp decline, with investors actively discussing potential market manipulation and the risks of holding tokens following accusations of a rug pull. The community remains deeply divided, with some traders hunting for a bounce while others warn of a total collapse and criticize the project's circulating supply structure.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is trending as investors rally around Greenland's approval of the company's increased 92.5% stake in the Tanbreez rare earth deposit, a move many believe de-risks the asset and bolsters Western mineral supply chain security. The community is actively debating potential short squeeze dynamics and arguing that the current valuation fails to fully account for the project's strategic significance and long-term earnings potential.

Daddy Darth Sidious

SIDIOUS is gaining traction alongside DARTH as part of a themed 'Daddy Darth' sector, with the community actively promoting these nano-cap tokens as speculative weekend runners. Investors are debating the risks of these low-liquidity assets while frequently rotating profits between related tokens in hopes of catching a breakout.

Definium Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.

Definium Therapeutics Inc.

Definium Therapeutics is experiencing intense market interest following a new executive order that fast-tracks the regulatory review process for psychedelic-based mental health treatments. Community discussions are split between excitement over potential fast-track vouchers and long-term pipeline readouts, and deep skepticism rooted in the company's past management controversies and concerns regarding potential share dilution.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Eli Lilly is experiencing significant market attention following its latest Phase 3 trial data for retatrutide, which demonstrated substantial weight loss and A1C reduction in type 2 diabetes patients without reaching a plateau. While the company's long-term dominance in the obesity and diabetes sector remains a core talking point, investors are closely monitoring competitive pressure from Novo Nordisk and regulatory scrutiny regarding potential safety profiles.

Chainlink is the industry-standard decentralized oracle network that solves the "oracle problem" by connecting smart contracts with real-world data. Blockchains cannot access external information on their own, so Chainlink acts as a secure bridge, enabling smart contracts to react to real-world events using verified, tamper-proof data. It is widely considered one of the first decentralized oracle networks and is the market leader in bringing off-chain data on-chain.  The platform operates through a decentralized network of nodes that fetch, validate, and deliver data to smart contracts. When a contract requests information like a stock price, a committee of independent nodes retrieves and aggregates the data to reach consensus, then delivers a single trustworthy answer. Chainlink offers a suite of services including Data Feeds for asset prices, CCIP for cross-chain token transfers and messaging, Automation for triggering smart contract functions, and Proof of Reserve for verifying asset collateralization.  Chainlink has established itself as critical infrastructure for both DeFi and institutional adoption, with partnerships including Swift, Euroclear, Mastercard, UBS, ANZ, Fidelity International, and J.P. Morgan. Its institutional products include the Chainlink Runtime Environment for tokenized asset workflows, Confidential Compute for privacy-preserving computation, and the Automated Compliance Engine for embedding regulatory rules into smart contracts.  The LINK token is the native asset used to pay node operators for services, fund subscription accounts, and incentivize network security through staking. Node operators stake LINK as collateral, which can be slashed if they provide inaccurate data. Chainlink was co-founded in 2017 by Sergey Nazarov and Steve Ellis, who co-authored the white paper with Ari Juels, and raised $32 million in its September 2017 ICO.

ChainLink

Chainlink is garnering attention as the infrastructure layer for institutional finance, highlighted by the integration of SIX Group's massive real-time equities data onto the blockchain. The community is actively debating its role in RWA tokenization and its potential to serve as the critical bridge for TradFi, while concurrently navigating broader market volatility and speculation regarding future regulatory impacts.

Rayls is a Layer-1 blockchain ecosystem designed for financial institutions to bridge traditional finance (TradFi) and decentralized finance (DeFi). Developed by Parfin, Rayls combines a public chain, private networks, and institutional privacy nodes into a unified infrastructure that supports compliant, scalable, and privacy-preserving asset tokenization and settlement. Its architecture connects regulated banks and payment systems with public DeFi liquidity while maintaining confidentiality through the Rayls Enygma privacy protocol. The network enables tokenization of real-world assets, CBDCs, and stablecoins using EVM-compatible technology, fixed USD-pegged gas fees, deterministic finality, and harmful MEV protection.

Rayls

Rayls is generating significant community conversation as investors speculate on its potential for institutional adoption in the RWA space following its recent listing on major exchanges. While some participants are actively buying on perceived price bottoms, others are debating whether the volatility and recent volume patterns signal an imminent breakout or indicate a lack of long-term stability.

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Compass Pathways Plc - ADR

COMPASS Pathways

COMPASS Pathways is trending following a presidential executive order designed to fast-track FDA reviews and expand research funding for psychedelic therapies. The community is actively discussing the stock's potential for clinical acceleration, with many focused on its status as one of the few players to successfully complete two Phase 3 trials and its positioning for upcoming regulatory catalysts.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

SPDR Gold Shares (GLD) is trending as investors weigh geopolitical risks in the Strait of Hormuz against hopes for a ceasefire, prompting discussions on whether the asset is regaining its traditional role as a safe-haven hedge. Market participants are closely analyzing options flow and institutional positioning to gauge if gold's recent price action signals a broader flight to quality amid persistent concerns over inflation and energy supply shocks.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul><li>H.C. Wainwright stated that it “reshapes the regulatory calculus” for the company’s Huntington’s disease gene therapy, AMT-130.</li><li>The firm stated that it has “continued conviction” in AMT-130's existing dataset and uniQure's broader pipeline.</li><li>Analysts at Chardan nearly doubled their price target for uniQure to $31 from $16, while keeping a ‘Buy’ rating, citing Prasad’s departure for its optimism.</li></ul>uniQure NV stock continued to draw retail buzz after analysts at H.C. Wainwright noted on Tuesday that the shares are poised for a value inflection following the reported departure of a key U.S. Food and Drug Administration (FDA) official.According to TheFly, analysts at H.C. Wainwright reiterated their ‘Buy’ rating and a $70 price target for the stock, implying a potential upside of nearly 289% from Monday’s closing price.<a href="https://stocktwits.com/symbol/QURE">uniQure shares</a> were up nearly 7% in Tuesday’s pre-market trade after a 26% surge on Monday.<h2 class="st-heading-2">Why Is HC Wainwright Bullish?</h2>H.C. Wainwright stated that the departure of Vinay Prasad, the head of the FDA’s division of vaccines and gene therapies at the end of April, bodes well for uniQure, stating that it “reshapes the regulatory calculus” for the company’s Huntington’s disease gene therapy, AMT-130.H.C. Wainwright stated that it has “continued conviction” in AMT-130's existing dataset and uniQure's broader pipeline.Prasad is reportedly leaving the agency next month to return to academia.Analysts at Chardan nearly doubled their price target for uniQure to $31 from $16, while keeping a ‘Buy’ rating. The firm cited Prasad’s departure as the reason for its price target hike.Earlier this month, the&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-qure-stock-almost-halve-pre-market-today/cZd344CRIcD">FDA&nbsp;</a>said it does not agree that uniQure’s Phase I/II data for AMT-130 are sufficient to serve as theprimary evidence of effectiveness for a marketing application for its Huntington’s disease gene therapy.“While we did not reach alignment on a submission pathway based on the Phase I/II data, we believe the totality and durability of our data warrant continued substantive dialogue regarding how the FDA’s stated commitment to regulatory flexibility may be appropriately applied in this setting,” said uniQure CEO Matt Kapusta.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits around uniQure trended in the ‘bullish’ territory at the time of writing.One user stated that this is the “gene therapy trade reset traders waited for.”<stembedurl>https://stocktwits.com/TradeThePool/message/647080386</stembedurl><a href="https://stocktwits.com/symbol/QURE">QURE stock</a> is down 25% year-to-date, but up 45% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/bill-ackman-pershing-square-files-for-ipo-after-a-delay-of-more-than-a-year/cZdoYmJRIeU">Bill Ackman’s Pershing Square Files For IPO After A Delay Of More Than A Year</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the uniQure logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

QURE Stock’s Relentless Rally Continues Today — Here's Why HC Wainwright Is Bullish On uniQure

H.C. Wainwright stated that the reported departure of a key U.S. Food and Drug Administration official at the end of April bodes well for uniQure.

Equity

<ul class="summary-bullets"><li>uniQure added that the FDA has recommended that the company conduct a prospective, randomized, double-blind, sham-surgery-controlled study.</li><li>The company stated that it intends to continue engaging with the FDA regarding Phase III trial development.</li><li>uniQure added that it plans to request a Type B meeting in the second quarter of 2026 to further discuss potential study design approaches.</li></ul>uniQure NV (QURE) shares plunged by nearly 45% in Monday’s pre-market trade after the company issued an update about its investigational gene therapy for Huntington’s disease (HD).uniQure said the FDA does not agree that Phase I/II data, compared with an external control, are sufficient to serve as primary evidence of effectiveness for a marketing application for its Huntington’s disease gene therapy, AMT-130.“While we did not reach alignment on a submission pathway based on the Phase I/II data, we believe the totality and durability of our data warrant continued substantive dialogue regarding how the FDA’s stated commitment to regulatory flexibility may be appropriately applied in this setting,” said uniQure CEO Matt Kapusta.Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/QURE">uniQure</a> trended in the ‘extremely bullish’ territory, with message volumes at ‘extremely high’ levels.<h2 class="st-heading-2">FDA Urges Sham-Controlled Trial</h2>uniQure added that the FDA has recommended that the company conduct a prospective, randomized, double-blind, sham-surgery-controlled study.The company stated that it intends to continue engaging with the FDA regarding Phase III trial development. uniQure added that it plans to request a Type B meeting in the second quarter of 2026 to further discuss potential study design approaches.“We remain committed to engaging with the FDA to determine a clear, scientifically grounded, and efficient path forward for AMT-130,” Kapusta added.<h2 class="st-heading-2">uniQure’s Gene Therapy Pipeline</h2>uniQure currently has six gene therapies in its pipeline, each at different stages of progress and approvals.The company’s Hemophilia B gene therapy, AMT-061, has already been approved, and the AMT-130 therapy for Huntington’s disease is currently at the most advanced stage of trials.uniQure’s other gene therapies include treatments for Fabry disease, Amyotrophic Lateral Sclerosis, and Temporal Lobe Epilepsy, apart from other undisclosed programs.<a href="https://stocktwits.com/symbol/QURE">QURE stock</a> is down 35% year-to-date, but up 29% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-is-aes-stock-falling-today-blackrock-gip-eqt-deal/cZd3EuiRIcw">Why Is AES Stock Falling Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Why Did QURE Stock Almost Halve Pre-Market Today?

uniQure said the FDA does not agree that Phase I/II data are sufficient to serve as primary evidence of effectiveness for a marketing application for its Huntington’s disease gene therapy, AMT-130.

<ul class="summary-bullets"><li>Analysts said Medicare’s drug-price cuts were smaller or already reflected in forecasts.</li><li>Pricing updates for major therapies from Novo Nordisk, Teva, AbbVie, and others eased sector worries.</li><li>Retail traders on Stocktwits turned extremely bullish on LABU as message volume surged.</li></ul>The biotech sector rallied sharply on Wednesday after Wall Street analysts said the latest round of U.S. Medicare drug-price cuts would have a smaller impact on pharmaceutical companies than initially feared, lifting the Direxion Daily S&amp;P Biotech Bull 3X Shares ETF (LABU) to its highest level in nearly 20 months.The&nbsp;<a href="https://stocktwits.com/symbol/LABU">LABU ETF</a> extended its rally on Wednesday, rising 3.7% to close at $165.5 and edging up 0.2% after hours, marking its fourth straight session of gains.<h2 class="st-heading-2">Bernstein Says Semaglutide Pricing Is ‘Final Cloud To Clear’</h2>Shares of major drugmakers jumped after the U.S. government published negotiated Medicare prices for 15 drugs late Tuesday, with cuts of up to 85% scheduled to begin in 2027.Novo Nordisk’s U.S.-listed shares rose&nbsp;nearly 4%, and Teva Pharmaceuticals gained over 5%, after their flagship therapies appeared on the pricing list. Novo’s semaglutide drugs, Ozempic and Wegovy, along with Teva’s Austedo, were included among the treatments subject to reductions.Bernstein analyst Christian Moore said the negotiated price for Novo’s semaglutide was “the final cloud to clear on the drawn-out, but positively resolved GLP-1 pricing debate,” Reuters&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/business/healthcare-pharmaceuticals/novo-shares-rise-us-medicare-price-cuts-come-largely-expected-2025-11-26/">reported</a>.<h2 class="st-heading-2">Goldman Sachs Says Austedo Cut Milder Than Expected</h2>Goldman Sachs analyst Matt Dellatorre noted that Austedo’s 38% price cut came in lower than the roughly 45% reduction modeled. He said the updated government price, which is a little over $700 lower per monthly supply versus one estimate of its net price, was below expectations and therefore less damaging for Teva.<h2 class="st-heading-2">Guggenheim Flags Deeper Than Expected Cuts For AbbVie</h2>Guggenheim analyst Vamil Divan said AbbVie’s cuts on Linzess and Vraylar, which come up to 75% and 44%, respectively, were deeper than anticipated.Two analysts said they are now watching how Medicare plans will manage access to the first batch of 10 drugs whose new negotiated prices take effect in January 2026, and what the Feb. 1 announcement of the next 15 drugs for 2028 will reveal.<h2 class="st-heading-2">Bernstein, William Blair, And Others Say Impact Already Priced In</h2>Bernstein analysts said five of the 15 targeted medicines will be generic by 2027, limiting exposure to deeper cuts. They added that lower prices could keep patients on branded therapies longer, potentially supporting volumes.William Blair analysts said the $274 monthly Medicare price for Novo’s semaglutide broadly tracks recent government agreements but added that insurance-coverage expansion remains uncertain. Analysts also said reductions had already been reflected in forecasts for Novo Nordisk, AstraZeneca and GSK.&nbsp;Earlier this month, Novo said it expected a low single-digit global sales impact if pricing were implemented this year, which analysts indicated translates to roughly DKK 6 billion.<h2 class="st-heading-2">Liquidity Wave Drives LABU Frenzy On Stocktwits</h2>On Stocktwits, retail sentiment for LABU was ‘extremely bullish’ amid ‘extremely high’ message volume.<figure class="image"><img style="aspect-ratio:970/143;" src="https://news.stocktwits-cdn.com/labu_ss_png_d696fb5c91.webp" alt="labu ss.png" width="970" height="143"><figcaption>LABU sentiment and message volume as of November 26 | Source: Stocktwits</figcaption></figure>One user said, “This concentrated burst of purchasing power is pushing up prices.”<stembedurl>https://stocktwits.com/JesusHolbrook/message/637590765</stembedurl>Another user said the move looks close to a blow-off top, possibly around $165–$175, and warned that any pullback could echo the sharp drop seen after the Covid peak.<stembedurl>https://stocktwits.com/bottomfishtrader/message/637525624</stembedurl>The LABU ETF has risen 22% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

The LABU ETF has risen 22% so far in 2025. (Photo credit: Getty Images)

Biotech Bull ETF Surges To 20-Month High: Analysts Say Medicare’s Drug-Pricing Blow Is Softer Than Feared

Pricing updates for major therapies from Novo Nordisk, Teva, AbbVie, and others eased sector worries.

Best-Performing Leveraged ETFs of October 

October's top ETF gainers included the likes of NVTX, AMUU, KORU, LABU and INTW. These ETFs soared as AI, crypto and reform optimism drove markets higher.

<ul class="summary-bullets"><li>The agency approved the medicine for both adults and pediatric patients with acute myeloid leukemia who are 1 year or older and have a susceptible nucleophosmin 1 (NPM1) mutation.</li><li>In the second quarter, Revuforj achieved $28.6 million in net revenue, representing a 43% increase over the first quarter of 2025. &nbsp;</li></ul>The U.S. Food and Drug Administration on Friday said that it has approved Syndax Pharmaceuticals’ (SNDX) Revuforj for some relapsed or refractory acute myeloid leukemia (ACL) patients with particular mutations.The agency <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-revumenib-relapsed-or-refractory-acute-myeloid-leukemia-susceptible-npm1-mutation">approved</a> the medicine for both adults and pediatric patients one year and older with a susceptible nucleophosmin 1 (NPM1) mutation who have no satisfactory alternative treatment options. &nbsp;<h2 class="st-heading-2">Implication For Patients, Syndax</h2>According to Syndax, mutations in the NPM1 gene are the most common genetic alteration observed in AML, occurring in approximately 30% of adults with the condition. Patients with the mutation have a poor prognosis, and there are currently no approved therapies that selectively target the underlying disease mechanism driving the cancer, it said.Revuforj was launched in the U.S. in November 2024 for the treatment of a specific type of leukemia called relapsed or refractory acute leukemia with a KMT2A translocation in adult and pediatric patients one year and older. The new FDA approval expands the indication for the drug.In the second quarter, Revuforj achieved $28.6 million in net revenue, representing a 43% increase over the first quarter of 2025.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Shares of the company soared 4% on Friday morning at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/SNDX">SNDX stock</a> stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume improved from ‘high’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:583/60;" src="data:image/png;base64,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" width="583" height="60" alt="SNDX's Sentiment Meter and Message Volume as of 1:39 p.m. ET on Oct. 24, 2025 | Source: Stocktwits"><figcaption>SNDX's Sentiment Meter and Message Volume as of 1:39 p.m. ET on Oct. 24, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user believes the stock is a good buy below $20.<stembedurl>https://stocktwits.com/dcrown/message/633624243</stembedurl>Another raised doubts about the possibility of a major rally.<stembedurl>https://stocktwits.com/Olena/message/633527864</stembedurl>SNDX stock is up by 15% this year but down by about 20% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/teladoc-stock-shoots-up-bofa-views-it-as-differentiated-asset-but-cautious-on-near-term-outlook/cLGJuuUR3ti">Teladoc Stock Shot Up 8% Today: BofA Views It As Differentiated Asset But Remains Cautious On Near-Term Outlook</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

SNDX Stock Is The Talk Of The Town Today: Here’s Everything To Know About The Latest FDA Approval 

The agency approved the medicine for both adults and pediatric patients with acute myeloid leukemia who are 1 year or older and have a susceptible nucleophosmin 1 (NPM1) mutation.

Leveraged ETF Areas of Last Week That Are Up At least 15%

Tech rally, weak jobs data and Fed rate cut bets were highlights of last week. Winning leveraged ETFs were GDXU, SOUX, AVGG, GGLL and LABU.

LABU
Direxion Daily S&P Biotech Bull 3X Shares

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest LABU News

LABUDirexion Daily S&P Biotech Bull 3X Shares